SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Perspectives on Cost and Value in Cancer Care · Study

WorkPerspectives on Cost and Value in Cancer Care

Leonard B. Saltz2015

Work2015

Perspectives on Cost and Value in Cancer Care

Leonard B. Saltz

51 citations·0/0 files stored·JAMA Oncology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Economic and Financial Impacts of Cancer Health Systems, Economic Evaluations, Quality of Life Healthcare cost, quality, practices

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 51 citations exist upstream.

References

2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)2015Pricing in the Market for Anticancer Drugs 2015The $2.6 Billion Pill — Methodologic and Policy Considerations 2015Five Years of Cancer Drug Approvals 2012Who Will Have Health Insurance in the Future? An Updated Projection

Cited by

2019Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China 2021Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2018Financial toxicity and implications for cancer care in the era of molecular and immune therapiesreview · 3 shared references 2016ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europearticle · 3 shared references 2017Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworksarticle · 3 shared references 2017How Much Longer Will We Put Up With $100,000 Cancer Drugs?article · 3 shared references 2018Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Timearticle · 3 shared references 2017The high price of anticancer drugs: origins, implications, barriers, solutionsreview · 2 shared references

Details

Year2015

Typeeditorial

Published2015-10-22

VenueJAMA Oncology

ISSN-L2374-2437

Languageen

Citations51

Files0 public / 0

ShelfEconomic and Financial Impacts of Cancer

Identifiers

doi10.1001/jamaoncol.2015.4191

openalex_workW2176371725

Links

Imported from OpenAlex (CC0) — nothing here is generated.